| Original language | English |
|---|---|
| Pages (from-to) | e839-e842 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 34 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2020 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the European Academy of Dermatology and Venereology, Vol. 34, No. 12, 12.2020, p. e839-e842.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - European Task Force on Atopic Dermatitis (ETFAD)
T2 - treatment targets and treatable traits in atopic dermatitis
AU - Thyssen, J. P.
AU - Vestergaard, C.
AU - Deleuran, M.
AU - de Bruin-Weller, M. S.
AU - Bieber, T.
AU - Taieb, A.
AU - Seneschal, J.
AU - Cork, M. J.
AU - Paul, C.
AU - Flohr, C.
AU - Weidinger, S.
AU - Trzeciak, M.
AU - Werfel, T.
AU - Heratizadeh, A.
AU - Barbarot, S.
AU - Darsow, U.
AU - Simon, D.
AU - Torrelo, A.
AU - Chernyshov, P. V.
AU - Stalder, J. F.
AU - Gelmetti, C.
AU - Szalai, Z.
AU - Svensson,
AU - von Kobyletzki, L. B.
AU - De Raeve, L.
AU - Fölster-Holst, R.
AU - Cristen-Zaech, S.
AU - Hijnen, D.
AU - Gieler, U.
AU - Ring, J.
AU - Wollenberg, A.
N1 - Funding Information: Dr. Thyssen has attended advisory boards for Eli‐Lilly, Regeneron, Pfizer, LEO Pharma, Abbvie and Sanofi‐Genzyme, received speaker honorarium from LEO Pharma, Abbvie, Regeneron and Sanofi‐Genzyme, and received research grants from Regeneron and Sanofi‐Genzyme. Dr. Vestergaard has been investigator, speaker or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. Deleuran has been a principal investigator, speaker, advisory board member and/or consultant for LEO Pharma, AbbVie, Almirall, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Morphosys‐Galapagos, Pierre Fabre and MEDA. Dr. de Bruin‐Weller M has been a principal investigator, advisory board member and consultant for Regeneron Pharmaceuticals Inc., UCB, Pfizer, and Sanofi Genzyme and a principal investigator, advisory board member for AbbVie. She has received grants or research support from Regeneron Pharmaceuticals and Sanofi‐Genzyme. Dr. Bieber has been a principal investigator, advisory board member or consultant for Regeneron, Sanofi, GSK, Celgene, Abbvie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVerSys, Galderma, Kymab, Glenmark, Astellas, Daiichi‐Sankyo, Lilly, Pfizer, MenloTx, Dermavant and Allmiral. Dr. T. Bieber was speaker, and/or consultant and/or investigator for AbbVie, Allmiral, AnaptysBio, Arena, Asana Biosciences, Astellas, BioVerSys, Böhringer‐Ingelheim, Celgene, Daichi‐Sankyo, Dermavant/Roivant, DermTreat, DS Pharma, RAPT/FLX Bio, Galapagos/MorphoSys, Galderma, Glenmark, GSK, Incyte, Kymab, LEO, Lilly, L´Oréa, MenloTx, Novartis, Pfizer, Pierre Fabre, Sanofi/Regeneron and UCB. T. Bieber is founder of the non‐profit biotech company ‘Davos Biosciences’. Dr Taïeb has been consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson, Incyte, Abbvie, Modilac, Pfizer, Lilly, Arena, Bioderma and Sanofi. Dr. Seneschal has been investigator, speaker or consultant for Novartis, Abbvie, Sanofi, LeoPharma and Eli Lilly. Dr. Weidinger has received institutional research grants from LEO Pharma and L‘Oreal, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Incyte, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Regeneron, LEO Pharma, Abbvie and Galderma, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of atopic dermatitis. Dr. Trzeciak has been a speaker for LEO Pharma, L’Oreal and Pierre Fabre and was involved in clinical trials for Pfizer, Regeneron and Novartis. Dr. Cork is an Investigator and Consultant for Regeneron, Sanofi Genzyme, Pfizer, Leo, Galapagos, Novartis, Boots, L’Oreal, Dermavant, Menlo, Reckitt Benckiser, Oxagen, Johnson&Johnson, Hyphens, Astellas, Abbvie, Galderma, Procter&Gamble. Dr Paul has received grants and been consultant for Allmiral, Amgen, Abbvie, Boehringer, Celgene, Eli Lilly & Co, Novartis, Janssen, Pfizer, LEO Pharma, Merck, UCB pharma, Pierre Fabre, Regeneron and Sanofi‐Genzyme. Dr Flohr is chief investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER ( Clinicaltrials.gov : NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a principal investigator in the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). His department has also received funding from Sanofi‐Genzyme. Dr. Heratizadeh received lecture and/or consultancy fees from LEO Pharma, Novartis, Pierre Fabre, Sanofi‐Genzyme, Beiersdorf, Hans Karrer, Nutricia, Meda and Lilly. Dr Barbarot has been a principal investigator, advisory board member or consultant for Pierre Fabre Laboratory, Bioderma, Laboratoire La Roche Posay, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo‐Pharma, Pfizer, Amgen and Lilly. Dr. Darsow gave advice to or received an honorarium for talks or research grant from the following companies: ALK‐Abello, Bencard, Meda, Novartis, and Sanofi‐Regeneron outside the submitted work. Dr. Simon has been an investigator, advisory board member or consultant for AbbVie, AstraZeneca, Galderma, Lilly, Pfizer, Roche Pharma and Sanofi Genzyme. Dr. Torrelo has acted as advisor and/or participant in clinical trials for Sanofi, Lilly, Pfizer and Abbvie. Dr. Chernyshov, Dr. Stalder and Dr. Svensson report no conflict of interest. Dr. Gelmetti has acted as advisor and/or participant in clinical trials for Bayer, Sanofi/Regeneron, Galderma and has lectured at educational events sponsored by Pfizer and Leo Pharma. Dr Szalai has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma and Novartis, has lectured at educational events sponsored by Nutricia, and is involved in performing clinical trials with pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Dr. von Kobyletzki has been investigator, speaker or consultant for Pfizer, Sanofi, LeoPharma and Eli Lilly. Dr. De Raeve is a consultant, member of scientific advisory boards and/or received personal fees and non‐financial support from LEO Pharma, Pierre Fabre, Sanofi‐Genzyme and Bioderma. Dr. Fölster‐Holst reports being consultant/Advisor for Beiersdorf AG, Johnson&Johnson, LEO Pharma, Neubourg, Novartis Pharma AG, Nutricia, Pfizer Inc., Regeneron, Sanofi‐Aventis as well as speaker for Beierdsorf AG, LEO Pharma, Neubourg, Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer, Procter&Gamble, Regeneron and Sanofi‐Aventis. Dr Christen‐Zaechs has been an advisor, speaker or investigator for Galderma, L’Oreal, La Roche Posey, Pierre Fabre, Procter and Gamble and Sanofi‐Genzyme. Dr. Hijnen has been investigator, speaker or consultant for Abbvie, Eli Lilly, Incyte, LeoPharma, MedImmune/Astrazeneca, Pfizer, Sanofi and ThermoFisher. Dr. Gieler has received institutional research grants from Galderma, has performed consultancies for Sanofi‐Genzyme, Regeneron, LEO Pharma, Lilly, Abbvie and Novartis, has lectured at educational events sponsored by Sanofi‐Genzyme, Abbvie, Novartis, Sebamed and Galderma, and is involved in the organization of atopic dermatitis education programs in Germany for the treatment of atopic dermatitis. Dr. Ring has been an advisor or speaker for AbbVie, Allergika, Sanofi‐Genzyme, Pfizer, Bencard, LEO Pharma and Mylan. Dr. Wollenberg has been a principal investigator, advisory board member, or consultant for AbbVie, Almirall, Galderma, Hans Karrer, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, Lilly, Loreal, MedImmune, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This research was performed independently through the authors’ academic university and hospital affiliations.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85087298967&partnerID=8YFLogxK
U2 - 10.1111/jdv.16716
DO - 10.1111/jdv.16716
M3 - Letter
C2 - 32515512
AN - SCOPUS:85087298967
SN - 0926-9959
VL - 34
SP - e839-e842
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 12
ER -